THE JOURNAL OF INFECTIOUS DISEASES • VOL. 160, NO. 6 • DECEMBER 1989
© 1989 by the University of Chicago. All rights reserved. 0022-1899/89/6006-0040$01.00

INDEX TO VOLUME 160

Author index

Abacioğlu, H., 161
Ables, L., 1005
Abshire, T. G., 706
Achola, J. O. N., 380
Adamowicz, P., 199
Adler, S. A., 1
Ahmad, S., 1092
Albert, J., 724
Albert, M. J., 169
Albrecht, R. M., 538
Alder, J. D., 289
Allegra, C. J., 312
Altwegg, M., 145
Alvar, J., 560
Amman, A., 960
Anderson, J. F., 729
Anderson, K. P., 960
Anderson, L. J., 777, 938
Andremont, A., 274
Andrews, J., 171
Anwar, F., 634
Arditi, M., 1005
Arosemena, J. R., 599
Arvin, A. M., 770
Asano, S., 548
Ashdown, L. R., 253
Ashkenazi, S., 469
Ashley, R., 353
Ashworth, L. A. E., 838
Åsjö, B., 724
Athar, M. A., 858
Aydintug, M. K., 846
Bagby, G. J., 422
Bai, X.-F., 218
Bainton, B. G., 422
Baqueiro, H. O., 730
Baranton, G., 734
Barbour, A. G., 351
Barin, F., 363
Barnes, R., 662
Baskin, G. B., 405, 905
Bastuji-Garin, S., 557
Batteiger, B. E., 332
Baumgartner, J. D., 347
Beamer, A., 442
Beaver, J., 312
Bechet, J. M., 162
Bechtel, L. J., 1056
Belec, L., 385
Benach, J. L., 497
Benhamou, J.-P., 199, 559
Berberich, H., 348
Berg, A. T., 1064
Bergeron, M. G., 433
Berk, S. L., 1051
Berkley, S. F., 22
Berman, P. W., 960
Bernard, E., 904
Bernstein, J., 999
Berry, A., 876
Bertrand, A., 354, 727
Beutler, B., 818
Bhat, R. A., 37
Bianchi, A., 662
Bianchi, W., 170
Bienzle, U., 357
Blake, P. A., 131, 978
Blake, R. K., 136
Blaser, M. J., 460, 1083
Blazquez, J., 560
Bloom, B. R., 104
Blumberg, H. M., 725
Boarman, D., 312
Bodsworth, N., 577
Boelaert, J. R., 914
Bohnen, J. M. A., 142
Bohnhoff, M., 1012
Bonagura, V. R., 777
Bottone, E. J., 1037
Bouvier, M., 913
Bower, J. R., 243
Bradford, H. B., 978
Bradley, R. B., 832
Brandtzaeg, P., 58
Brauer, K. L., 95
Braun, M. M., 902
Bray, M. A., 715
Brazilian Purpuric Fever Study Group, 476
Bréchot, C., 199
Bres, P., 734
Bretaña, A., 104
Bricaire, F., 557
Brodsky, L., 999
Brook, I., 651, 1071
Brown, E., 644
Brown, R., 353
Brunka, J., 627
Brunton, J. L., 433
Bryan, L., 627
Bryant, H. E., 858
Burney, M. I., 634
Buser, M., 414
Bysani, G. K., 52
Cagnoni, P., 559
Caillaux, M., 355
Cameron, W., 380
Campos, J., 810
Camus, D., 355
Cantey, J. R., 136
Capobianco, L. A., 1064
Carbone, K., 442
Carles, M., 904
Carlisle, J. T., 349
Carlone, G. M., 476
Carr, S. J., 1086
Carrigan, D. R., 741
Casaccia, P., 795
Casellato, R., 909
Casin, I., 662
Castellanos, P. L., 104
Castés, M., 104
Castilla, A., 165
Caubarrere, I., 162
Caussy, D., 599
Cavanagh, T. R., 1067
Certain, A., 507
Chabner, B., 312
Chadwick, E. G., 954
Chamberlin, W., 1030
Chandramuki, A., 343
Chanyangam, M., 810
Charet, P., 355
Chechani, V., 555
Chen, C.-R., 944
Chen, D.-S., 944
Chen, P.-J., 944
Chiba, S., 44, 611
Chou, S., 11, 16
Christou, N., 142
Cisneros, J. M., 907
Civeira, M.-P., 165
Claessens, M.-R., 553
Clark, R. A., 911
Cleary, T. G., 243, 469
Coburn, J. W., 914
Cohen, J. I., 887
Cohen, M. L., 1067
Cohn, D. L., 460
Colebunders, R. L., 902
Collins, M. S., 483
Congeni, B. L., 243
Conly, J. M., 721
Contini, C., 736
Convit, J., 104
Cook, R. L., 490
Coombs, R., 380
Cooney, C. A., 253
Corbeil, L. B., 846
Corey, L., 380
Cote, P. J., 572
Couderc, L. J., 162
Couroucé, A.-M., 199
Cover, T. L., 1083
Cox, N. J., 913
Craig, W. A., 616
Crijns, H. J. G. M., 150
Cross, A. S., 225

Crystal, R. G., 1042
Cubitt, W. D., 392
Cuello, J. A., 907
Cuevas, M., 599
D'Elia, R., 909
Dale, J. K., 1085
Daling, J. R., 328
Damsker, B., 1037
Daroca, P. J., 349
Daugherty, N., 289
Davis, J. A., 759
Davis, W. C., 846
Dawson, J. E., 803
de Koning, J., 150
de la Maza, M., 730
Decker, M. D., 832
Degos, F., 199
Degott, C., 559
deGroot, R., 810
Dei-Cas, E., 355
Deinhardt, F., 766
Dellamonica, P., 904
DeMaria, Jr., A., 348
Denis, F., 363
Denning, D. W., 344
Desgranges, C., 162
Devoto, S., 469
Di Prima, M. A., 736
Diaz, M., 469
Dickerson, N., 720
Dierich, M. P., 549
Dikilu, K., 902
Dinarello, C. A., 1085
Dong, H., 948
Donnenberg, M. S., 452
Donohue-Rolfe, A., 452
Donovan, B., 577
Downing, R., 22
Dublanchet, A., 554
Dunn, B. E., 1083
Duperval, R., 433
Dupont, W. D., 832
Durand, J., 904
Eastburn, R. L., 896
Edmonson, L. M., 298
Edwards, K. M., 832
Eichberg, J. W., 960
Ellison III, R. T., 1083
Elser, J. M., 657
Elwood, R. K., 345
Enarson, D. A., 345
Enelow, T. J., 349
Eng, T. R., 346
Eskola, J., 237
Evatt, B. L., 789
Ezzell, J. W., 706
Faden, H., 999
Fang, Z.-Y., 948
Farber, C. M., 556
Farinotti, R., 507
Farmer III, J. J., 145
Farrar, J. A., 938
Feinstone, S., 887
Feld, R., 433
Feldman, M., 1084
Fenves, A. Z., 914
Fenyö, E. M., 724
Ferguson, D., 160
Fernandez-Villar, B., 497
Fields, D. H., 803
Fierer, J., 722
Filice, G. A., 305
Filion, L. G., 398
Fine, D. P., 76
Fisch. A., 554
Fishbein, D. B., 803
Fishman, M., 52
Fitzgerald-Bocarsly, P., 1084
Flehmig, B., 209
Fleischer, B., 209
Flynn, T., 1056
Ford, E., 938
Ford, E. G., 1037
Formica, S., 104
Fox, K., 442
Freeman, K., 826
French, M. L. V., 678
Fritsche, T., 896
Fuchs, D., 724
Fujioka, K., 1086
Gallin, M. Y., 521
Gallo, R. C., 550
Garcia, M., 599
Garcia-Monco, J. C., 497
Garris, R., 876
Garver, P. L., 442
Gaytán, J. J. A., 730
Gdula, W. J., 371
Geelen, L., 237
Gelb, L. D., 535
Genta, R. M., 692
Georges, A. J., 385
Gerberding, J. L., 321
Gerding, D. N., 1087
Gerin, J. L., 567, 572
Gerna, G., 159
Gershon, A. A., 535
Gershy-Damet, G., 363
Ghafoor, A., 634
Giaquinto, C., 909
Gibbs, Jr., C. J., 371
Giller, R. H., 919
Girard, M., 199
Girard, P.-M., 507, 559
Glass, R. I., 392, 948
Glauser, M. P., 347
Gloster, E. S., 476
Goetz, M. B., 1090
Gohd, R. S., 349
Gomes, T. A. T., 131
Gomez, M. A., 559
Gordon, S., 1030
Gormus, B. J., 405
Goudeau, A., 199
Granoff, D. M., 634
Granowitz, E. V., 910
Grayston, J. T., 328
Greater Boston Otitis Media Study Group, 83
Green, J. A., 543
Greene, B. M., 521
Greene, N. R., 803
Greene, R. T., 346
Greer, D. L., 911
Gregory, T., 960
Griffin, A., 686
Griffith, B. P., 160
Griffith, S. J., 1030
Grinstein, S., 469
Grose, C., 919
Grossi, P., 159
Guerrant, R. L., 460
Guillot, E., 507
Gunn, R. A., 978
Gussetti, N., 909
Guthertz, L. S., 1037
Gyr, K., 414
Haeberli, A. 865
Hager, C. C., 832
Hamill, R. J., 538
Hammerschlag, M. R., 535
Hansen, E. J., 818
Hanson, C. V., 960
Happ, C. M., 970
Harada, S., 901
Harding, G., 433
Hargrett-Bear, N., 994
Haroche, G., 554
Harris, J. P., 929
Harris, O. N., 289
Harrison, J. L., 669
Harrison, L. H., 706
Hasan, M., 1092
Hasegawa, A., 611
Hatano, M., 611
Hatch, D. L., 711
Hautekeete, M. L., 559
Hawey, A. E., 686
Hayden, F. G., 700
Healy, D. P., 876
Hector, R. F., 483
Hedberg, C. W., 298
Hemophilia-AIDS Collaborative Study Group, 789
Henderson, D. K., 321
Hendley, J. O., 644
Hendrix, C. W., 442
Hendry, R. M., 185
Hengstler, B., 715
Hermans, P. E., 752
Herndon, J. L., 978
Hickman-Brenner, F. W., 145
Hierholzer, J., 938

Hildner, W. K., 52
Hirsch, M. S., 1056
Ho, M.-S., 948
Hoadley, D. J., 911
Hoffman, P. N., 545
Hoge, C. W., 985
Holmberg, S. D., 116
Holmes, K. K., 380
Holmes, K. V., 759
Honda, T., 1089
Hong, J. J., 999
Hoogkamp-Korstanje, J. A. A., 150
Hook III, E. W., 530
Horsburgh, Jr., C. R., 116
Horton, P., 720
Howell, D., 1084
Huemer, H. P., 549
Huggler, E., 865
Hugon, J., 363
Hung, T., 948
Hurwitz, E., 938
Huskins, K. R., 1056
Ibiary, S. E., 686
Iinuma, H., 66
Inman, L. R., 136
Inzana, T. J., 846
Ishaq, Z., 634
Israel, E., 985
Izaguirre, C. A., 398
Izu, A., 960
Jacobs, R. F., 657
Jaffe, H. W., 116
Janbon, F., 354, 727
Janda, J. M., 1037
Janney, F. A., 911
Jason, J., 789
Jayasimhulu, K., 95
Jilg, W., 766
Jimenez-Mejias, M. E., 1088
Johns, M. A., 348
Johnson, B. J. B., 970
Johnson, C. M., 153
Johnson, R. W., 253
Johnson, S., 1087
Jones, D. B. W., 298
Jones, R. B., 332
Jonsen, A. R., 205
Jordan, M. C., 305
Josephs, S. F., 550
Kabeer, M., 634
Kabins, S., 1030
Kadurugamuwa, J. L., 715
Kamholz, S. L., 555
Kaneda, Y., 735
Kaneko, S., 903
Karthas, N., 1056
Kass, E. H., 1061
Kato, Y., 735
Katz, B. P., 332
Katz, B. Z., 589
Katz, J. M., 191
Kaufmann, A. F., 706
Kawamoto, H., 44
Kawasaki, T., 900
Kellogg, D. E., 954
Kemp, A., 803
Kendrick, M. I., 1061
Kennedy, C. A., 1090
Kernan, W. N., 442
Keusch, G. T., 452
Khan, H. M., 1092
Khanna, R., 1092
Kidd, S., 706
Kierulf, P., 58
Kikuta, H., 546, 550
Kimura, Y., 611
King, C. H., 686
Kinloch, S., 913
Kitchen, L. W., 911
Kiyota, H., 1061
Klein, J. O., 83
Klein, R. S., 826
Kline, S., 305
Kloser, P., 1084
Klotz, S. A., 669
Kobayashi, J. M., 994
Kobayashi, K., 611
Kobayashi, N., 44
Koehler, J. M., 253
Koehrn, F. J., 929
Kohl, S., 770
Kohler, R. B., 678
Korba, B. E., 572
Kosloff, B. R., 1056
Kovacs, J. A., 312, 882
Kreiss, J. K., 380
Kremsner, P. G., 357
Krilov, L. R., 777
Krom, R. A. F., 752
Kron, M. A., 521
Krueger, G. R. F., 722
Krystofik, D., 999
Kumaraswami, V., 1042
Kwok, S., 954
Labia, R., 274
Labidi, A., 281
Ladogana, A., 795
Lafaix, C., 554
Lalonde, R. G., 433
Lamaury, I., 727
Lambert, H. P., 838
Landis, S. J., 433
Laplanche, A., 199
Larcher, C., 549
Larkin, D. P., 545
Larsen, J. H., 900
Law, C., 513
Lawrence, D. N., 789
Le Fichoux, Y., 904
Leach, A., 169
Leaf, H. L., 356
Leclerq, B., 274
Leggett, J. E., 616
Leggiadro, R. J., 448
Lennington, W., 332
Lenti, L., 736
Léonard, F., 274
Léonard, G., 363
Leport, C., 557
Letonja, T., 846
Levine, P. A., 700
Levine, P. H., 722
Lew, D. P., 865
Lewis, J. H., 994
Lewis, M., 312
Li, D.-k., 328
Liberski, P. P., 371
Libonati, J. P., 985
Lietman, P. S., 442
Likanonsakul, S., 392
Lillibridge, J. P., 692
Linnan, M. L., 22
Liu, H., 289
Lomberg, H., 1082
Londe, H. F., 960
London, W. T., 604
Loo de Lao, S., 599
Loo, L. S., 770
Lopez, E. L., 469
Low, D. E., 433
Lowry, P. W., 978
Lu, H., 550
Lucas, C., 960
Lucas, S., 913
Ludwig, J., 752
Maassab, H. F., 604
MacDonald, K. L., 298
Mack, D., 37
Mackenzie, R. K., 1081
MacLean, J. D., 513
MacLowry, J. D., 624
Maddison, S. E., 171
Maehara, N., 543
Maggiolo, F., 170
Magnarelli, L. A., 729
Mahdi, A. A., 1092
Mahmoud, A. A. F., 686
Maier, K., 209
Mäkelä, P. H., 237
Makino, S., 543
Mandell, L. A., 433
Marbet, G. A., 414
Marcellin, P., 559
Marche, C., 557
Marcoux, L., 777
Marie, F.-N., 199
Marr, J. J., 153
Marrie, T., 433
Martin, L. N., 405
Martin, P. M. V., 385
Martin, T. R., 261
Martinez, A., 907
Masala, C., 736

Masur, H., 312, 882
Mathewson, J. J., 243
Mathisen, G., 1090
Mathison, J. B., 978
Matlow, A. G., 142
Matsumoto, K., 611
Matsumoto, S., 546, 550
Maude, D., 826
Maupin, G. O., 970
Maury, W., 583
McCabe, W. R., 348
McCarthy, R. E., 657
McCracken, Jr., G. H., 818, 891
McFarland, L. M., 978
McGowan, Jr., J. E., 546
McIntosh, K., 185, 1056
McKhann II, G., 371
McLean, R. H., 448
McVoy, M. A., 1
Meakins, J., 142
Mellors, J. W., 160
Memo, L., 909
Mendilaharzu, F., 469
Mera, J., 559
Mertsola, J., 818, 891
Meyers, W. M., 405
Michel, M. D., 559
Midura, T. F., 1037
Miedzinski, L. J., 433
Milch, L. J., 351
Miller, E., 838
Miller, G., 589
Miller, R. H., 903
Minekawa, Y., 44
Misasi, R., 736
Misra, R. P., 669
Mitani, K., 548
Mitchell, R., 344
Miwatani, T., 1089
Miyazono, K., 548
Mojon, M., 736
Mollnes, T. E., 58
Monath, T. P., 970
Mondain, V., 904
Montali, R. J., 759
Moore, J. L., 789
Mora, C. A., 371
Morel, P., 662
Morello, J. A., 1012
Morisset, R., 553
Morita, M., 44
Morita, O., 44
Morris, Jr., J. G., 985
Morrison, H. T., 332
Mosher, D. F., 538
Mougeot, G., 355
Mounier, M., 363
Muepu, K., 902
Mulder, G. D., 358
Murphey-Corb, M., 405
Murphy, B. R., 604
Murray, B. E., 243, 469
Musser, J. M., 237, 634
Mustafa, M. M., 818, 891
Nagakura, K., 735
Najera, R., 560
Nakamura, Y., 900
Nakanishi, M., 546
Nakata, S., 611
Nakayama, T., 543
Nakayama, Y., 166
Napoli, V. M., 546
Nathan, C., 1030
Nawawi, M. E., 686
Negro, F., 567
Neill, M. A., 994
Nelson, D. J., 153
Nelson, K. E., 938
Nelson, S., 422
Newhall V, W. J., 332
Newland, H. S., 521
Ngugi, E., 380
Ni, Y., 1089
Nicolle, L. E., 627
Nightingale, B. N., 577
Nikora, B., 380
Nohr, C., 142
Nomani, N. K., 634
Nutman, T. B., 1042
Nydegger, U. E., 865
Nzila, N., 902
Offit, P. A., 783
Ogra, P. L., 999
Ohnmeiss, H., 170
Ohseto, M., 44
Okinaga, K., 66
Okuyan, M., 161
Okware, S. I., 22
Osano, M., 543
Osterholm, M. T., 298
Ostroff, S. M., 994
Ottesen, E. A., 1042
Ou, C.-Y., 789, 970
Overturf, G. D., 711
Ozawa, K., 548
Pachón, J., 907
Pachon-Diaz, J., 1088
Pahwa, S. G., 126
Pai, C. H., 858
Palmer, P. S., 832
Parenti, D. M., 1076
Parrillo, J. E., 312
Pascaud, M. B., 507
Pattishall, K. H., 153
Patton, C. M., 460
Paya, C. V., 752
Paz, H. M., 153
Peeler, R. N., 985
Peltier, B. H., 978
Peñaranda, M. E., 392, 948
Pennington, J. E., 453
Percivalle, E., 159
Perez, C., 727
Perez-Perez, G. I., 460
Perfect, J. R., 912
Perol, Y., 662
Perronne, C., 557
Peter, J. B., 1085
Peters, B., 721
Peterson, L. R., 1087
Petty, B. G., 442
Pialoux, G., 559
Pica, R. V., 126
Pickering, L. K., 243, 469
Pierik, L. T., 185
Pinardi, M. E., 104
Pinkston, P., 1042
Pittet, D., 865
Plummer, F., 380
Pocchiari, M., 795
Poisson, M., 553
Politano, S., 904
Polk, R. E., 876
Pollard, C., 826
Pomeroy, C., 305
Pond, D. G., 490
Potts, B. J., 583
Prazuck, T., 554
Prieto, J., 165
Prober, C. G., 770
Proctor, R. A., 538
Purcell, R. H., 567, 572, 887
Qing, S., 948
Quan, T. J., 727
Quiroz, E., 599
Qureshi, A. W., 634
Raab-Traub, N., 589
Raad, I., 727
Rabson, A. B., 583
Rakela, J., 752
Ramilo, O., 818, 891
Ramsay, E. C., 759
Raoult, D., 354, 734
Rawls, W. E., 599
Read, R. C., 344
Read, S. E., 551
Rechnitzer, D., 521
Redus, M. A., 803
Reeves, W. C., 599
Reibnegger, G., 724
Reid, G., 490
Reig, R., 810
Reller, L. B., 460
Renneberg, J., 337
Reusser, P., 414
Revello, M. G., 159
Rey, J.-L., 363
Reynes, J., 354
Reynes, J., 727
Richman, D. D., 929
Riker, D. K., 700
Rimland, D., 725
Risser, R. C., 818, 891

Roberts, N. C., 978
Rodgers-Johnson, P. E., 371
Rodríquez, N., 104
Rogers, M. D., 153
Ronald, A. R., 433
Roncoroni, A. J., 559
Rondón, A., 104
Rosa, P. A., 1018
Rose III, R. C., 720
Rosner, B., 83
Rowe, P. C., 448
Rubeglio, E., 469
Rubin, L. G., 476
Rufus, K., 52
Ruga, E., 909
Ryder, R., 902
Sadoff, J. C., 225
Saenz, R. E., 153
Sáez-Llorens, X., 342
Sáez-Llorens, X., 891
Saginur, R., 398, 433
Sahai, J., 876
Saif, L., 392
Sakiyama, Y., 546
Sakurada, N., 44
Saliou, P., 199
Salmon, D., 557
Samuel, D., 545
Sande, M. A., 555
Sands, M., 353
Sangaré, F., 363
Sarubbi, F., 1051
Sasaki, K., 543
Satterfield, W. C., 567
Sawyer, J., 686
Scheidegger, D., 414
Schell, R. F., 289
Schell, W. A., 912
Schiavone, A., 551
Schiffman, G., 826
Schmidt, M., 766
Schmidt, R. A., 261
Schmitt, C. A., 490
Schochetman, G., 789
Schwan, T. G., 1018
Scieux, C., 662
Sciortino, C. V., 248
Selander, R. K., 237, 634, 1030
Selwyn, P. A., 826
Sempala, S., 22
Septimus, E. J., 733, 908
Seto, B., 37
Shapiro, E. D., 1064
Shapiro, M., 567, 572
Shaunak, S., 912
Shenep, J. L., 52
Shigematsu, I., 900
Shore, A., 551
Shuff, C., 999
Sidberry, H., 225
Silcox, V. A., 281
Simberkoff, M. S., 356
Sinarachatanant, P., 392
Singh, V., 727
Skerrett, S. J., 261
Skolnik, P. R., 1056
Slade, H. B., 126
Smith, A. L., 810
Smith, C. R., 442
Smith, S., 720
Smith, T. F., 752
Sninsky, J. J., 37, 954
Snyder, M. H., 604
Sobel, J. D., 490
Soike, K. F., 905
Sorice, M., 736
Soro, B., 363
Sorrentino, J. V., 700
Soulez, B., 355
Sperber, S. J., 700
Spielman, A., 166
Stanievich, J., 999
Staudt, M., 513
Steadman, R., 1081
Steel, C., 1042
Steele, L. C., 281
Steenman, G., 385
Steinberg, S. P., 535
Steiner, B. M., 289
Stephensen, C. B., 759
Stierhof, Y.-D., 209
Stokes, D. C., 52
Stone, R. T., 243
Straus, S. E., 722, 1085
Stringfield, P. C., 678
Stroup, D. F., 978
Subirá, M. L., 165
Sullender, W. M., 770
Summer, W. R., 422
Suzuki, E., 901
Svanborg Edén, C., 1082
Svoboda, Y. M., 783
Tachibana, H., 735
Takahashi, T., 548
Takaku, F., 548
Takala, A. K., 237
Tan, M., 521
Tancrède, C., 274
Taniguchi, K., 44
Tarr, P. I., 994
Tauxe, R. V., 1067
Taylor, D. N., 392
Taylor, H. R., 521
Taylor, J. C., 832
Teele, D. W., 83
Teitel, J. M., 551
Tenover, F. C., 810
Terhune, Jr., C. A., 896
Thomas, J. C., 1086
Thomas, M. G., 838
Threlkeld, M., 442
Tokieda, M., 44
Toma, E., 553
Toorkey, C. B., 741
Topley, N., 1081
Torronteras, R., 1088
Trabulsi, L. R., 131
Tremblay, M., 31
Tron, F., 199
Trouvin, J.-H., 507
Trygg, C. B., 405
Tsai, R. R., 95
Tsang, V. C., 171
Turco, M., 469
Ujack, E., 627
Ulrich, M., 104
Ulrich, P. P., 37
Unnasch, T. R., 521
Urano, T., 543
Urasawa, S., 44
Urasawa, T., 44
Valainis, G. T., 349
Valecillos, L., 104
Vallbracht, A., 209
van Alphen, L., 237
van der Linde, M. R., 150
Van, R., 433
Van Savage, J., 832
Vann, J. M., 538
Vartian, C. V., 733, 908
Vasquez, M., 469
Vaudaux, P., 865
Vega, C., 433, 553
Ventura, M. G., 556
Verdier, M., 363
Verghese, A., 1051
Vernant, J. C., 162
Veterinary Laboratory Investigation Center, 706
Viallet, J., 513
Viciana-Fernandez, P., 1088
Vieira, M. A. M., 131
Viering, T. P., 76
Vijayan, V. K., 1042
Vildé, J. L., 557
Vullo, V., 736
Vyas, G. N., 37
Wachsmuth, I. K., 131
Wachter, H., 549, 724
Wainberg, M. A., 31
Wakasugi, F., 44
Walder, M., 337
Waldvogel, F. A., 865
Wallace, Jr., R. J., 281
Walsh, G. P., 405
Wang, S.-p., 328
Wanger, A., 243
Ward, J. W., 116
Warren, D., 938
Waterman, S. H., 1086
Watsky, D., 985
Watt, G., 343
Webb, P. A., 970

Webster, R. G., 191
Wedgwood, J. F., 777
Weinberg, G. A., 634
Weinstein, R. A., 1030
Wen, L., 948
Wenzel, R. P., 644
West, M. S., 770
Wheat, L. J., 678
White, A. T., 521
White, K. E., 22, 298
Widy-Wirsky, R., 22
Wiedmann, K. H., 209
Wiesner, R. H., 752
Wiggins, L. H., 896
Williams, J. D., 1081
Winistorfer, S., 919
Winkelstein, J. A., 448
Wisniewski, T. L., 911
Wiström, J., 732
Wittenberg, D. F., 342
Wolinsky, S. M., 954
Woloj, M., 469
Wolz, S. A., 616
Wong, B., 95
Wood, R. A., 448
Woolf, N. K., 929
Worley, M., 759
Wright, P. F., 832
Wu, M. M., 347
Wurtz, R. M., 555
Wybran, J., 556
Yamamoto, N., 901
Yamamoto, T., 168
Yamazaki, S., 611
Yanagawa, H., 900
Yanagi, K., 901
Yang, P.-M., 944
Yang, W.-S., 218
Yao, Z.-Q., 218
Ye, Q., 948
Yogev, R., 954, 1005
Yoh, M., 1089
Yokota, T., 168
Yoshida, T., 901
Yoshiyama, H., 901
Young, C. L., 163
Young, L. S., 430
Zak, O., 715
Zaninovic, V., 371
Zavattoni, M., 159
Zhang, J.-y., 405
Zhang, W.-B., 218
Zimmerli, W., 414
Zimmerman, S. E., 678
Zitt, M. Q., 1064

THE JOURNAL OF INFECTIOUS DISEASES • VOL. 160, NO. 6 • DECEMBER 1989
© 1989 by the University of Chicago. All rights reserved. 0022-1899/89/6006-0041$01.00

Subject Index

Abscess, cerebellar, due to *B. melitensis*, 730
Acquired immunodeficiency virus (*See AIDS*)
Adenitis, due to BCG, in AIDS, 727
Adenovirus
  enteric, in SIV-infected monkeys, 905
  in AIDS, and respiratory failure, 349
  keratoconjunctivitis, nosocomial outbreak, 938
Adherence
  C. albicans, to endothelium and platelets, 669
  in *E. coli* (EPEC), 131
  in *E. coli*, nonpiliated mutant, 136
  S. aureus
    on catheters, host factors, 865
    role of fibrinogen, fibrin, and fibronectin, 865
    to bovine endothelial cells, 538
  V. cholerae, in intestinal M cells, 168
AIDS
  adenitis, due to BCG, 727
  and invasive infection by *T. beigelii*, 356
  and *M. avium* and *M. intracellulare* infections, 1037
  deficient interferon-α production but normal NK cell A activity, 1084
  neonatal, pathogenesis of infection, 583
  nosocomial infection, due to penicillin-resistant pneumococci, 725
  potential for insect transmission of HIV, by bedbugs, 970
  prophylactic zidovudine, 321
  respiratory failure due to adenovirus, 349
  simian, interaction with leprosy, 405
  transmission of HIV, lack of evidence for urine as a route, 1056
  vaccine, HIV-1 recombinant gp120, effect of dose and schedule, in baboons, 960
AIDS Commentary
  HIV in rural Tennessee, 1051
  prophylactic zidovudine, 321
  prophylaxis for PCP, 882
  risk factors in sexual transmission, 116
  syphilis and HIV infection, 530
AIDS-related complex, encephalopathy with sulfadiazine, 163
Alcoholism, acute and chronic, effects on TNF and the inflammatory response, 422
Allopurinol, for visceral leishmaniasis, in AIDS, 904
Allopurinol riboside, for American cutaneous leishmaniasis, 153
Amphotericin B
  for pulmonary blastomycosis, 911
  for scrapie, in hamsters, 795
  suppression of scrapie replication, in hamster, 795
Ampicillin, for mixed infection, related to β-lactamase production, in mice, 337
Anaerobic infection, β-lactamase production, prevents alterations in flora by antibiotics, 274
Animal model
  baboons, immunization against AIDS with HIV-1 recombinant gp120, 960
  Brazilian purpuric fever, due to *H. influenzae* in infant rats, 476
  guinea pig, congenital CMV infection, 929
  L. pneumophila, in corticosteroid-treated rats, 261
  P. carinii, in young rabbits, 355
  pentamidine administration, in rats, 507
  subcutaneous abscess due to *B. fragilis–E. coli* mixed infection, treatment for, in mice, 652
Anthrax, cutaneous, serologic diagnosis, 706
Antibiotic resistance, R-plasmid epidemiology in *H. influenzae*, 810
Antibiotics
  ampicillin and mixed infection, 337
  ceftriaxone and intestinal flora, 274
  cephalosporins, clinical trials, 430
  P. multocida, susceptibility, 353
  spiramycin and *Cryptosporidium*, 342
  susceptibility and efficacy, for *B. fragilis–E. coli* mixed infections, in mice, 651
Antibody
  response to
    filariae, localized to the lung, 1042
    pneumococcal vaccine, in AIDS and HIV infection, 826
    recombinant gp120 of HIV-1, in baboons, 960
    varicella glycoproteins, 919
    HIV, in vaginal secretions, 385
    HTLV-1, in Ivory Coast populations, 363
    LPS, in gram-negative bacteremia, 225
Antibody-dependent cellular cytotoxicity antibody, neonatal, associated with neonatal HSV, 770
Antibody-mediated enhancement, of RSV, in monocytes/macrophages, 777
Anticardiolipin antibodies, in *P. carinii* infection, 736
Antihistamine, effect of pretreatment, on vancomycin-induced red-man syndrome, 876
Ascites, *L. loa* microfilariae in, 559
Aspergillosis
  D-mannitol, diagnostic marker, 95
  experimental infection, in rats, 95
Aspergillus fumigatus, infection, in rats, 95
Azidothymidine, effect on HIV-1, in vitro, 31

Bacille Calmette-Guérin, adenitis, in AIDS, 727
Bacillus anthrax, infection, serologic diagnosis, 706
Bacteremia
  anaerobic, in military hospitals, 1071
  due to
    Bacteroides species, in military hospitals, 1071
    Clostridium species, in military hospitals, 1071
    non-O:1 *V. cholerae*, 732
    Peptostreptococcus species, in hospitals, 1071
    S. pneumoniae, prevention by vaccine, 66
  gram-negative, antibodies to LPS, 225
Bacterial infections, treatment with third-generation cephalosporins, 430, 433, 442
Bactericidal test, use of serum ultrafiltrate in serum dilution test, 616, 624
Bacteroides fragilis, and *E. coli*, mixed infection in a subcutaneous abscess model, in mice, 652
β-lactamase
  in intestinal organisms, resistance to colonization, 274
  protection against mixed infection, in mice, 337
Blastomyces dermatitidis, and *M. tuberculosis* in HIV-1, 911
Bordetella pertussis
  efficacy of pertussis vaccine, in infants and children, 832
  serologic response after vaccination, 838

Borrelia burgdorferi
adherence to glial cells, 497
analysis of serotypes, 351
detection by PCR, 1018
ingestion by *I. dammini*, on infected hosts, 166
risk of infection, in dogs, 346
seropositivity and lameness, in dogs, 346
spirochetes, in cardiac biopsy, 150
Brazilian purpuric fever, due to *H. influenzae* biogroup aegyptius, infant rat model, 476
Brucella melitensis
aortic endocarditis, 907
cerebellar abscess, 730

C-reactive protein, levels in neonates, 909
Campylobacter, enterotoxin and cytotoxin in human enteritis, 460
Candida albicans, adherence to endothelium and platelets, 669
Cefotaxime, and ceftriaxone, for serious infections, 433
Ceftizoxime, and ceftazidime, for *H. influenzae* meningitis, in infants, delayed CSF sterilization, 711
Ceftriaxone
and cefotaxime, for serious infections, 433
effect on inflammation in *H. influenzae* type b meningitis, in rabbits, 818
effects on intestinal flora, in humans and gnotobiotic mice, 274
iv, for *H. influenzae* meningitis, 1005
Central nervous system, infection due to scrapie, treatment with amphotericin B, in hamsters, 795
Cephalosporins, third-generation, clinical trials, 430, 433, 442
Chlamydia pneumoniae, transmission and sexual behavior, 328
Chlamydia trachomatis
and *C. pneumoniae*, 328
serovar and inflammation, 332
Chronic fatigue syndrome
circulating lymphokine levels, 1085
expression of CD3, 165
postviral, 722
Ciprofloxacin, photosensitivity rash, 910
Clearance studies, *L. pneumophila*, in steroid-treated rats, 261
Clostridium difficile
diarrhea or colitis, after iv metronidazole, 1087
potential treatment with quinolones, 170
Clue cells, *G. vaginalis*, immunofluorescent identification, 490
Complement activation, and endotoxin levels in meningococcal disease, 58
Complement deficiency (C4B), association with meningitis, 448
Complement-mediated inflammation, in experimental meningitis, rabbits, 715
Coxiella burnetii
concomitant infection with *R. conorii*, 354
false-positive serology in parenteral drug addicts, 1088
Cryptococcus, meningitis, artifactual elevation of serum creatinine, in treatment with flucytosine, 1090
Cryptococcus neoformans, meningitis, normal CSF, 912
Cryptosporidium
enteritis, spiramycin for, 342
infection, in renal transplant patients, 559
Cytomegalovirus
age-related reactivation, in seropositive, immunocompetent individuals, 1
antigen, early immediate, as marker, 741
early antigen detection by immunofluorescence, 159
hearing loss due to congenital infection, in guinea pigs, 929
hepatitis, in liver transplant recipients, 752
immunosuppression by, reactivation of *T. gondii*, 305
latency, through reactivation and recombination of strains, 11
latent infection, in human tissues, 741
neutralizing antibody response in transplant recipients, 16

Day care center, outbreak of diarrhea due to *E. coli*, 243
Deferoxamine, complication in dialysis patients, mucormycosis, 914
Dexamethasone, effect on inflammation in *H. influenzae* type b meningitis, in rabbits, 818
Diarrhea
due to
C. jejuni, 460
E. coli, adherent, EPEC, 131
E. coli, adherent, pathogenesis, 452
E. coli, EIEC, 169
E. coli, nonadherent, 136
E. coli O114:nonmotile, 243
rotavirus, group C, in Thailand, Nepal, and England, 392
rotavirus, human, in Japan, 44
rotavirus, outbreak in China, 948
T. nativa, new clinical syndrome, 513
Vibrio species, a prospective study among meeting attendees, 978
or colitis, due to *C. difficile*, after iv metronidazole, 1087
DNA restriction endonuclease banding patterns, genetic analysis of serotypes in *S. pneumoniae*, 76

Editorial, clinical trials of broad-spectrum antibiotics, 430
Ehrlichia canis, infection, surveillance, in febrile hospitalized patients, 803
Ehrlichiosis
concurrent positive serology with Lyme disease, 727
human, surveillance, in febrile hospitalized patients, 803
ELISA
diagnosis of
clinical and subclinical melioidosis, 253
mycobacteria, 343
sensitivity and specificity in melioidosis, 253
Endocarditis, aortic, due to *B. melitensis*, 907
Endomyocarditis, due to Lyme disease, 150
Endophthalmitis, due to *P. multocida*, 733
Endothelium, adherence of *C. albicans*, 669
Endotoxin, levels and complement activation in meningococcal disease, 58
Enterococcus, pathogenicity, in fecal peritonitis, 142
Epidemiology
C. pneumoniae and sexual behavior, 328
C. trachomatis serovar and inflammatory response, 332
central venous catheters, in a community hospital, association with dressing, 720, 721
diarrhea due to
E. coli O114:nonmotile, in a day care center, 243
group C rotavirus, in Thailand, Nepal, and England, 392
Vibrio species, prospective study, 978
E. coli O157:H7, risk factors for infection, in an urban community, 858
G. lamblia, transmission, in a nursing home, 298

gastroenteritis, due to group C rotavirus, in schoolchildren, 611
genital infection due to HPV, in Panama City prostitutes, 599
group A streptococci, community-acquired, 1086
H. influenzae type b infection, incidence and age distribution, in Finland, 237
hemolytic uremic syndrome and diarrhea, in Argentine children, 469
heterogeneity of mycobacterial isolates in surgical infections, 281
HIV infection, risk factors, in Uganda, 22
human ehrlichiosis, prospective active surveillance, in hospitalized patients, 803
intensity of infection and response to purified antigen vaccine, in a chronically infected Egyptian population, 686
isolation of HIV from genital ulcers, in Nairobi prostitutes, 380
keratoconjunctivitis due to adenovirus, nosocomial outbreak, 938
nosocomial infections, role of gastric colonization, 414
occupational exposure to HIV, prophylactic zidovudine for, 321
otitis media, pediatric, in Boston, 83
outbreak of cutaneous anthrax, in Paraguay, 706
P. aeruginosa, in oncology patients in a general hospital, 1030
prevalence of antibody to HTLV-1, in Ivory Coast populations, 363
prevalence of HIV-1 in hemophilic men and their sex partners, 789
respiratory tract infection, in Pakistani children, 634
rotavirus, adult diarrheal outbreak, in China, 948
rotavirus, serotypes in Japan, 44
RSV, prevalence of subgroups during outbreaks, 185
S. typhi, rRNA gene restriction patterns, 145
serotype-specific prevalence of EPEC, in Brazil, 131
shigellosis, outbreak on a Hopi Indian reservation, 1067
transmission of HIV, lack of evidence for urine as a route, 1056
trichinosis in the Canadian Arctic, 513
Vibrio species, infections in a Chesapeake Bay community, 985
Epstein-Barr virus DNA
latent and replicating forms, 589
lymphomas and lymphoproliferative disorders, 589
Errata
Griswold et al., J Infect Dis 1989;159:1083–1087, 1095
Hammerschlag et al., J Infect Dis 1989;160:535–537, 1095
Inderlied et al., J Infect Dis 1989;159:994–997, 1095
Ray et al., J Infect Dis 1989;159:829–836, 564
Wong et al., J Infect Dis 1989;160:95–103, 916
Escherichia coli
and *B. fragilis*, mixed infection, polymicrobial treatment, 652
antibodies to outer membrane proteins, 627
EHEC, hemolytic uremic syndrome and diarrhea, in children, 469
EIEC, staining with Congo Red, 169
EPEC
epithelial cell invasion associated with adherence, 452
serotypes and serogroups, 131
J5, murine monoclonal antibodies to, 846
nonadherent mutant, 136
O114:nonmotile, in diarrheal disease, 243
O157:H7
plasmid profiles and systemic sequelae, 994
risk factors for infection, in an urban community, 858
toxin genotypes and systemic sequelae, 994
virulence and renal scarring, 1081, 1082
Ethics, volunteers in high-risk research, 205
Exanthema subitum, immune response in patients to HHV-6, 901

Fibronectin, ultrastructural localization on *S. aureus*, 538
Filarial disease, due to *O. volvulus*, recombinant antigen, 521
Filariasis, due to *L. loa*, 559
Flucytosine, artifactual elevation of serum creatinine, in treatment for meningitis, 1090
Folate synthesis, in *P. carinii* and *T. gondii*, 312

Gardnerella vaginalis, clue cells, identification in bacterial vaginosis, 490
Gastroenteritis, due to group C rotavirus, 392, 611
Genital tract infection
C. trachomatis and inflammatory response, 332
due to *C. trachomatis*, 662
Genital ulcers, isolation of HIV from Nairobi prostitutes, 380
Gentamycin, intraventricular, for neonatal meningitis, 891
Giardia lamblia
characterization of a thiol proteinase, 1076
diarrhea, outbreak in a nursing home, 298
Glycoproteins, varicella-zoster virus, immunity to, 919
Gonococcal infection, strain serovars and serum resistance, 1012
Group A streptococci, community-acquired, 1086

Haemophilus influenzae (*See Hemophilus influenzae*)
Hantaan virus
hemorrhagic fever with renal syndrome, virus in body fluids, 218
viremia, hemorrhagic fever with renal syndrome and CNS infection, 218
Hemolytic uremic syndrome
and diarrhea, due to SLT-I and -II, 469
relation to *E. coli* O157:H7 toxin genotype, 994
Hemophilia, prevalence of HIV-1 in hemophilic men and their sex partners, 789
Hemophilus influenzae
biogroup aegyptius, Brazilian purpuric fever, 476
from children with lower respiratory tract infection, clonal analysis, 634
genetic relatedness of antibiotic resistance, 810
meningitis
endotoxin levels in CSF, 1005
treatment with ceftriaxone, 1005
otitis media, in children, 999
type b
experimental meningitis, modulation of inflammation and TNF activity, in rabbits, 818
immunogenicity of outer membrane complex, vaccine, 1064
invasive infection, in Finland, 237
meningitis, treatment with ceftizoxime and ceftazidime, delayed CSF sterilization, 711
virulence and LPS, 237
virulence and outer membrane proteins, 237
Hemophilus influenzae type b–*N. meningitidis* group B outer membrane complex conjugate vaccine, 1064
Hemorrhagic colitis, due to *E. coli* O157:H7, risk factors, 858
Hemorrhagic fever with renal syndrome, Hantaan virus, virus in body fluids, 218
Hepatitis A virus
cytotoxic T cells, liver-derived, in vitro, 209

infection, detection and viremia, in a chimpanzee, 887
possible oropharyngeal site for replication, 887
Hepatitis B virus
carrier chimpanzees, rechallenged with HDV, 567
chronic infection
concurrent with HIV, 577
core gene sequence, 903
detection by PCR, in humans and chimpanzees, 37
nucleotide sequence, heterogeneity in the core gene, 903
phytohemagglutinin mitogenic response, in normal vaccinees, 398
recombinant vaccine, 199
vaccine, comparison of three different vaccination schedules, 766
Hepatitis, callitrichid, due to a new primate virus, 759
Hepatitis D virus
reappearance due to rechallenge, 56
replication and interaction with HBV, 944
RNA transcription, in infected human liver, 944
Hepatitis
due to CMV, in liver transplant recipients, 752
epizootic, of marmosets and tamarins, 759
Hepatitis virus, woodchuck, LPS induction of infectious virions in cultured lymphocytes, 573
Herpes simplex virus, neonatal, antibody-dependent cellular cytotoxicity antibody levels, 770
Herpes zoster, infection in an adult recipient of live attenuated varicella vaccine, 535
Herpesviruses, latent infection, 741
Histoplasma capsulatum
diagnosis, by antigen detection in urine and serum, 678
polysaccharide antigen, comparison of radioimmunoassay and ELISA for detection, 678
Histoplasmosis, diagnosis, by *H. capsulatum* antigen detection, 678
Human herpesvirus 6, polypeptides, immune response of patients with exanthema subitum, 901
Human immunodeficiency virus
absence in urine of seropositive individuals, 1056
and syphilis, AIDS Commentary, 530
and visceral leishmaniasis, 560
antibody in commercial gamma globulin, 161
concurrent infection with chronic HBV, in homosexual men, 577
detection, in children, 954
false-negative ELISA, 160
heterosexual transmission, 385
in Epstein-Barr virus–transformed B cells, effect of AZT, 31
in rural Tenessee, AIDS Commentary, 1051
infection
complicated by pulmonary blastomycosis, 911
congenital, asymptomatic, diagnosis, 126
maternal-fetal transmission, 583
of first-trimester and term placental tissue, 583
response to pneumococcal vaccine, 826
risk factors, in Uganda, 22
isolation from genital ulcers in Nairobi prostitutes, 380
local immunity, in vaginal secretions, 385
potential for insect transmission, by bedbugs, 970
recombinant gp120, immunization, effect of dose and schedule, in baboons, 960
replicative capacity and serum concentrations of neopterin, 724
sexual transmission, 116
Human immunodeficiency virus type 1, prevalence in hemophilic men and their sex partners, 789
Human immunodeficiency virus type 2, interferon-α production and NK activity, in AIDS, 1084
Human papillomavirus, genital infection, in Panama City prostitutes, 599
Human T lymphotropic virus type 1
detection of DNA by PCR, 162
encephalomyeloneuropathy, isolation and characterization, 371
heterosexual transmission, 363
isolation and characterization, from tropical spastic paraparesis patients, 371
prevalence of antibody, in Ivory Coast populations, 363
Human volunteers, ethics of use in high-risk research, 205

IgA
antibody to HIV, in vaginal secretions, 385
response to pertussin toxin, filamentous hemagglutinin, and agglutinogens, after infection and vaccination, 838
IgE
filarial-specific, levels in lower respiratory tract, in tropical pulmonary eosinophilia, 1042
polyclonal, in lower respiratory tract epithelial lining fluid, in tropical pulmonary eosinophilia, 1042
IgG
antibody levels, in CMV, 1
antibody to HIV, in vaginal secretions, 385
antibody to *S. stercoralis*, 692
filarial-specific, levels in lower respiratory tract, tropical pulmonary eosinophilia, 1042
response to pertussin toxin, filamentous hemagglutinin, and agglutinogens, after infection and vaccination, 838
IgM
antibody levels, in CMV, 1
filarial-specific, levels in lower respiratory tract, in tropical pulmonary eosinophilia, 1042
monoclonal antibody, treatment for pneumonia due to *P. aeruginosa*, 483
response to pertussin toxin, filamentous hemagglutinin, and agglutinogens, after infection and vaccination, 838
Immune response
in falciparum malaria, presence of soluble circulating CD8, 357
in treponemal infection, role of macrophage, 289
S. minnesota rough mutant R595, protective role, 347
Inflammation
and cachectin activity in experimental *H. influenzae* type b meningitis, in rabbits, 818
due to *C. trachomatis* infection, correlation with serovar, 332
Influenza A virus, efficacy of inactivated (H3N2) vaccines, 191
Influenza B virus
cold-adapted reassortant, in hamsters and chimpanzees, 604
temperature sensitivity, attenuation, and phenotypic stability, 604
Informed consent, and evaluation of risk-benefit ratio in research, 205
Interferon, circulating levels in chronic fatigue syndrome, 1085
Interferon-α
deficient production, but normal NK activity, in AIDS, 1084
nomenclature, 543
Interferon-β, recombinant, nasal drops for prophylaxis of natural colds, 700
Interferon-γ, nomenclature, 543

Interleukin 1β, in coliform neonatal meningitis, correlation with outcome, 891
Interleukin, circulating levels in chronic fatigue syndrome, 1085
Ixodes dammini, ingestion of *B. burgdorferi*, 166

Kawasaki disease, relation to *Yersinia* species, 900
Keratoconjunctivitis, due to adenovirus, nosocomial outbreak, 938

Labyrinthitis, due to congenital CMV infection, in guinea pigs, 929
Legionella pneumophila, impaired clearance, in steroid-treated rats, 261
Leishmania braziliensis panamensis, treatment with allopurinol, 153
Leishmania donovani infantum, infection in HIV, 560
Leishmaniasis
  American cutaneous, immunotherapy versus chemotherapy, 104
  treatment with allopurinol, noncomparative clinical trial, 153
  visceral
    and HIV, 560
    treatment with allopurinol, in AIDS, 904
Leprosy, interaction with simian AIDS virus, 405
Leptospirosis, serologic diagnosis, comparison of techniques, 734
Lipopolysaccharide
  antibody response, in gram-negative infection, 225
  core determinants, 225
  cross-reactivity with murine monoclonal antibodies to *E. coli* J5, 846
  H. influenzae type b and virulence, 237
  induction of infectious woodchuck hepatitis virus in cultured lymphocytes, 572
  inhibition of TNF, 52
Loa loa, microfilariae, in ascitic fluid, 559
Lyme disease
  adherence of spirochete to glial cells, 497
  concurrent positive serology with ehrlichiosis, 727
  detection of *B. burgdorferi* by PCR, 1018
  endemic areas for, 729
  spirochetes in cardiac biopsy, 150
  ticks, ingestion of spirochetes, 166
Lymphocyte
  alveolar, detection of HTLV-1, 162
  CD3 in chronic fatigue syndrome, 165
  peripheral blood, LPS induction of woodchuck hepatitis virus in culture, 573
Lymphogranuloma venereum
  due to *C. trachomatis*, 662
  infection in men, presenting with inguinal adenopathy or proctitis, 662
Lymphomas, EBV viral DNA in, 589

Macrophage
  alveolar, inhibition of TNF release by polymyxin B, 52
  antimicrobial activity, in CMV-induced reactivation of toxoplasmosis, in mice, 305
  phagocytosis, *T. pallidum pertenuae*, 289
Magnesium, effect on production of exoprotein and β-lactamase by *S. aureus* and *S. hemolyticus*, 1061
Malaria, cerebral, eye involvement, 1092
Mammaplasty, mycobacterial wound infection, 281
Melioidosis, diagnosis by ELISA, compared to other tests, 253
Meningitis
  bacterial, due to C4B deficiency, in children, 448
  cryptococcal
    artifactual elevation of serum creatinine with flucytosine, 1090
    normal CSF, 912
  due to *H. influenzae*, endotoxin levels in CSF, 1005
  due to *H. influenzae* type b
    delayed sterilization of CSF, in infants, 711
    experimental, in rabbits, 818
  increased leukocytes and protein in CSF, in rabbits, 715
  neonatal, coliform, treatment with intraventricular gentamycin, 891
Meningococcal disease, systemic, due to *N. meningitidis*, complement activation and endotoxin levels, 58
Monoclonal antibodies
  enhancement of RSV infection, in macrophage-like cell lines, 777
  murine, to *E. coli* J5, cross-reactivity with gram-negative bacteria and LPS, 846
  to hemolysins of *V. parahemolyticus* and *V. hollisae*, 1089
  to *V. cholerae* in animals, 248
Monoclonal antibody, IgM, treatment of pneumonia due to *P. aeruginosa*, 483
Monocytes/macrophages, antibody-mediated enhancement of RSV, 777
Mucormycosis, in dialysis patients, registry, 914
Mycobacteria, peritoneal infection, clinical features, 344
Mycobacterial
  infection, in mammaplasty, 281
  meningitis, due to *M. tuberculosis*, 343
Mycobacterium avium, and *M. intracellulare* infections, in AIDS, 1037
Mycobacterium intracellulare, and *M. avium* infections, in AIDS, 1037
Mycobacterium bovis, and AIDS, 727
Mycobacterium leprae, interactions with simian AIDS virus, 405
Mycobacterium tuberculosis, and *B. dermatitidis*, in HIV-1, 911
Myospherulosis, differential diagnosis, 913

Nanophyetus salmincola, infection, treatment with praziquantel, 896
Natural killer cell, normal activity but deficient interferon-α production, in AIDS, 1084
Neisseria meningitidis, systemic meningococcal disease, complement activation, 58
Neisseria gonorrhoeae, infection, strain serovars and serum resistance, 1012
Nematode, parasitic infection, *S. stercoralis*, 692
Neopterin, association between serum concentrations and replication of HIV, 724
Neurobrucellosis, due to *B. melitensis*, 730
Nosocomial infection
  adenoviral keratoconjunctivitis, 938
  central venous catheters, associated with dressing, 720, 721
  due to *P. aeruginosa*, in oncology patients, 1030
  penicillin-resistant pneumococci in AIDS, 725
  role of gastric colonization, in patients on mechanical ventilation, 414
Nursing home, outbreak of giardiasis, 298

Onchocerca volvulus, clinical correlates with antigen immune recognition, 521
Onchocerciasis, serum reactivity with *O. volvulus* recombinant antigens, 521
Opportunistic infection
L. pneumophila, in steroid-treated rats, 261
P. carinii and *T. gondii*, folate metabolism, 312
toxoplasmosis, reactivation in mice challenged with CMV, 305
Organ donors, CMV latency, reactivation and recombination, 11
Organ transplant recipients, neutralizing antibody response to CMV, 16
Osteochondritis, due to *Pseudomonas*, foot puncture wounds, in children, 657
Otitis media
due to *H. influenzae*, in children, 999
influencing factors in pediatric infection, 83
Outer membrane proteins
H. influenzae type b, 237
E. coli, antibodies to, 627
V. cholerae, 248

Pasteurella multocida
endophthalmitis, 733
susceptibility to antimicrobials, in vitro, 353
Pentamidine mesylate
administration, aerosol and parenteral, in rats, 507
pharmacokinetic profile in tissue, 50
Peritoneal infection, due to *M. tuberculosis*, clinical features, 344
Peritonitis, fecal, pathogenicity, in rats, 142
Perspective
ethics of high-risk human research, 205
serum dilution test, 624
Pertussis
diagnosis, serologic, 838
serologic response after infection and vaccination, 838
Plasmodium falciparum, soluble CD8 in patients with malaria, 357
Plasmodium knowlesi, malaria, eye involvement, 1092
Platelets, adherence of *C. albicans*, 669
Pneumococcal infection, nosocomial, penicillin-resistant, in AIDS, 725
Pneumocystis carinii
folate metabolism as screen for therapeutic agents, 312
epitopes on, cross-reaction with cardiolipin, 736
nonimmunosuppressed model, young rabbit, 355
pneumonia, prophylaxis for, 882
Pneumonia, due to
L. pneumophila, in steroid-treated rats, 261
P. aeruginosa, treatment with a human IgM monoclonal antibody, 483
Polymerase chain reaction, to detect
B. burgdorferi, 1018
hepatitis B DNA, 37
HIV, in children, 954
HIV-1 DNA, 789
HTLV-I in alveolar lymphocytes, 162
Polymorphonuclear leukocyte, early antigen detection in CMV infection, 159
Polymyxin B, inhibition of TNF release in alveolar macrophages, 52
Praziquantel, for *N. salmincola* infection, 896
Prophylaxis, zidovudine for occupational exposure to HIV, 321
Prostaglandin E_2, effect on
C5a-induced inflammation in meningitis, 715
PMNL infiltration and protein extravasation in experimental meningitis, 715
Pseudomembranous colitis, potential treatment with quinolones, 170
Pseudomonas aeruginosa
colonization and infection, in oncology patients, 1030
pneumonia, treatment with a human IgM monoclonal antibody, 483
Pseudomonas, osteochondritis, from foot puncture wound, in children, 657
Pseudomonas pseudomallei, clinical and subclinical infection, diagnosis by ELISA, 253
Pulmonary blastomycosis, treatment with amphotericin B, 911

Quinolones, for pseudomembranous colitis, 170

Rash, photosensitivity, due to ciprofloxacin, 910
Raw milk, certified, in California, 722
Red-man syndrome, vancomycin-induced, effect of antihistamine pretreatment, 876
Renal transplantation, *Cryptosporidium* infection, 559
Respiratory syncytial virus
antibody-mediated enhancement, in monocytes/macrophages, 777
prevalence of subgroups during outbreaks, 185
Respiratory tract infection, lower, due to *H. influenzae*, clonal analysis, 634
Rhinovirus, infection, interferon-β nasal drops for, 700
Rickettsia conorii
concomitant infection with *C. burnetti*, 354
false-positive serology in parenteral drug addicts, 1088
Rickettsia typhi, false-positive serology in parenteral drug addicts, 1088
Rickettsiae, *E. canis* infection, 803
Rocky Mountain spotted fever, endemic areas for, 729
Rotavirus
adult diarrheal outbreak, in China, 948
cytotoxic T lymphocyte response, after vaccination, in mice, 783
group C, and diarrheal disease, 392
group C, gastroenteritis, in schoolchildren, 611
human serotypes, detection by ELISA, 44
rRNA gene restriction patterns, *S. typhi*, typing, 145

Salmonella minnesota, role of serum antibodies after immunization, 347
Salmonella typhi, rRNA gene restriction patterns, typing, 145
Schistosoma haematobium, concomitant infection with *S. haematobium*, and *S. japonicum*, 171
Schistosoma japonicum, concomitant infection with *S. haematobium*, and *S. japonicum*, 171
Schistosoma mansoni
concomitant infection with *S. haematobium* and *S. japonicum*, 171
vaccination against, with *S. mansoni* surface antigen, 686
Schistosomiasis
concomitant infection with *S. mansoni*, *S. haematobium*, and *S. japonicum*, 171
in a chronically infected Egyptian population, vaccine against, 686
Scrapie, treatment with amphotericin B, in hamsters, 795

Sepsis, due to group A streptococci, community-acquired, 1086
Septic bursitis, due to *S. marcescens*, 908
Serratia marcescens, septic bursitis, 908
Serum dilution test, use of serum ultrafiltrate, 616, 624
Shiga-like toxin genotype, in *E. coli* O157:H7 infections, 994
Shiga-like toxins, role in hemolytic uremic syndrome and diarrhea, in Argentine children, 469
Shigellosis, multiply resistant, due to gene transfer, 1067
Simian immunodeficiency virus, adenoviral infection, 905
Skin, normal flora, reservoir, 644
Spiramycin, for *Cryptosporidium* enteritis, 342
Staphylococcus aureus
  adherence, on catheters, host factors, 865
  effect of magnesium on production of exoprotein and β-lactamase, 1061
  ultrastructural localization of fibronectin, 538
Staphylococcus, coagulase-negative, plasmid profiles, 644
Staphylococcus hemolyticus, effect of magnesium on production of exoprotein and β-lactamase, 1061
Streptococcus pneumoniae
  analysis of serotypes by DNA restriction endonuclease banding patterns, 76
  bacteremia, prevention by capsular polysaccharide vaccine, in splenectomized rats, 66
  vaccination against in HIV-infected subjects, 826
Strongyloides stercoralis, prominence of IgG4 antibody to, 692
Strongyloidiasis, enhanced IgG4 response in infection, 692
Sulfadiazine, encephalopathy in ARC, 163
Sulfamethoxazole-trimethoprim, for *P. multocida*, 353
Syphilis, and HIV infection, AIDS Commentary, 530

T cell, cytotoxic, in hepatitis A, 209
T lymphocyte, cytotoxic response, to rotavirus, in mice, 783
Thrombotic thrombocytic purpura, relation to *E. coli* O157:H7 toxin genotype, 994
Toxin production, clinical and immunologic role in *Campylobacter* enteritis, 460
Toxin production, role in pathogenesis, by *Campylobacter*, 460
Toxocara canis, infection, due to ingestion of raw poultry, 735
Toxocariasis, due to *T. canis* via ingestion of raw poultry, 735
Toxoplasma gondii
  folate metabolism as screen for therapeutic agents, 312
  reactivation by CMV, 305
Treponema pallidum pertenue, phagocytosis by hamster macrophages, 289
Trichinosis, new clinical syndrome, 513
Trichosporon beigelii, in AIDS, 356
Trimethoprim-sulfamethoxazole, resistance in *Shigella*, 1067
Tropical pulmonary eosinophilia, analysis of antifilarial antibody localized to the lung, 1042
Tropical spastic paraparesis
  detection of HTLV-1 in alveolar lymphocytes, 162
  due to HTLV-1, symptomatic family members, 371
Tumor necrosis factor
  activity, and modulation of inflammation, in *H. influenzae* meningitis, 818
  circulating levels in chronic fatigue syndrome, 1085
  effect of polymyxin B, 52
  suppression of activity by alcohol, 422
TWAR, *C. pneumoniae*, 328

Urinary tract infection
  due to
    E. coli, 627
    E. coli, virulence and renal scarring, 1081, 1082
  in elderly patients, antibodies to *E. coli*, 627

Vaccine
  conjugate, against *H. influenzae* type b, 1064
  for AIDS, HIV-1 recombinant gp120, effect of dose and schedule, in baboons, 960
  hepatitis B virus
    comparison of three different vaccination schedules, 766
    recombinant, 199
    suppressed PHA response, 398
  inactivated influenza A virus, efficacy, 191
  leishmaniasis, American cutaneous, efficacy in controlled clinical trial, 104
  pertussis
    efficacy in infants and children, 832
    whole-cell, serologic response, 838
  pneumococcal
    response among HIV-infected subjects, 826
    response in AIDS, 826
  pneumococcal bacteremia, efficacy in splenectomized rats, 66
  rotavirus, T lymphocyte cytotoxic response, in mice, 783
  rough mutants of enterobacteriaceae, 348
  varicella, live-attenuated, subsequent development of zoster, 535
Vaginosis, bacterial, immunofluorescent identification of clue cells, 490
Vancomycin, cause of red-man syndrome, effect of antihistamine pretreatment, 876
Varicella-zoster virus, immunity to, in normal hosts, 919
Vibrio cholerae
  adherence to intestinal M cells, in vitro, 168
  monoclonal antibodies to outer membrane antigens, 248
  non-O:1, bacteremia, 732
  wound infection, 1083
Vibrio hollisae, immunologic cross-reactivity with *V. parahaemolyticus*, 1089
Vibrio parahaemolyticus, immunologic cross-reactivity with *V. hollisae*, 1089
Vibrio species
  epidemiology in a Chesapeake Bay community, 985
  gastroenteritis, a prospective study among meeting attendees, 978
Virulence, and renal scarring, in *E. coli*, 1081, 1082

Whooping cough, efficacy of pertussis vaccine, in infants and children, 832
World Health Organization, clinical case definition of AIDS, evaluation among patients with tuberculosis, 902
Wound infection due to
  mycobacteria, in mammaplasty, 281
  V. cholerae, 1083

Yaws, use of *T. pallidum pertenue* from patient with frambesiform infection, 289

Zidovudine, prophylaxis for occupational exposure to HIV, 321